Thalassemias

Treatment Considerations for Thalassemia in the Emergency Department

Antoine N. Saliba, MD, and colleagues summarized current literature surrounding the frequent complications that bring patients with thalassemia into the ED.

FDA Grants Orphan Drug Status to Mitapivat for Thalassemia

By

Brian Park, PharmD

The FDA has granted Orphan Drug designation to mitapivat (AG-348; Agios Pharmaceuticals) for the treatment of thalassemia.

Promising New Noninvasive Test Developed for β-Thalassemia in At-Risk Pregnancies

By

Lauren Dembeck, PhD

Compared to invasive prenatal diagnosis, a noninvansive assay may be a viable alternative for genotyping a fetus in pregnancy at high-risk for β-thalassemia.

Ferriprox Twice-a-Day Tablet Dosing Approved for Transfusional Iron Overload Due to Thalassemia Syndromes

By

Brian Park, PharmD

The FDA has approved a twice-a-day formulation of Ferriprox® (deferiprone; Chiesi) for the treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Altered Bone Marrow Microenvironment Induces Defect of Hematopoietic Stem Cells in β-Thalassemia

By

Dibash Kumar Das, PhD

For patients with β-thalassemia who undergo HSCT, exposure to a normal microenvironment and the impairment of HSCs may be reversible in the presence of a normal microenvironment and in vivo protein restoration.

Luspatercept Improves Transfusion Burden in Patients with Transfusion-Dependent Beta-Thalassemia

By

Lauren Dembeck, PhD

When compared with placebo, luspatercept increased the percentage of patients with transfusion-dependent beta-thalassemia who had a reduction in transfusion burden.

Managing Complications Associated With Increased Longevity in Beta Thalassemia

By

Roxanne Nelson, RN, BSN

As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.

Novel Conditioning Regimen for Haploidentical HSCT in Severe Thalassemia

By

Vicki Moore, PhD

Both event-free and overall survival at 3 years were 96% for patients with transfusion-dependent thalassemia who underwent transplant.

Mineral and Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major

By

Morgan E. Meissner

Hypothyroidism, hyperglycemia, and low adrenocorticotrophic hormone levels are associated with lower bone mass in patients with thalassemia major.

Improving Bone Mass With Iron Chelation Therapy in Transfusion-Dependent Beta Thalassemia

By

Vicki Moore, PhD

Iron chelation therapy with deferasirox and deferoxamine led to significant improvements in bone mineral density and serum ferritin levels.

As Survival Increases in Beta Thalassemia, Renal Complications Emerge

By

Roxanne Nelson, RN, BSN

Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.

Utility of Flow Cytometry to Detect Red Blood Cell Alloimmunization in Thalassemia

By

Sharon Ben Barouch, MD

Red blood cell alloantibodies were detected more than 4 times as frequently with flow cytometry compared with direct Coombs test.

Reducing Transfusion Burden and Addressing Unmet Needs in Beta Thalassemia

By

Caleb Rans, PharmD

Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.

White Matter Changes and Headache in Thalassemia

By

Sonali Gattani

Recurrent headache was reported by 61% of patients with thalassemia compared with 22.5% of healthy individuals in a control arm.

The Efficacy of Intrabone Gene Therapy for Transfusion-Dependent Beta Thalassemia

By

John Schieszer, MA

Allogeneic HSC gene therapy may be an alternative to transplantation for patients with transfusion-dependent thalassemia.

Luspatercept May Improve Hemoglobin Levels in Patients With Beta Thalassemia

By

John Schieszer, MA

A high percentage of patients with beta thalassemia demonstrated an increase in hemoglobin levels after receiving luspatercept.

New Iron Chelator May Improve Cardiac Function in Patients With Beta Thalassemia

By

Lauren Dembeck, PhD

A new oral iron chelator, deferasirox, may confer long-term benefits to patients with beta thalassemia major.

A Novel Health-Related Quality of Life Assessment Tool for Nontransfusion-Dependent Beta Thalassemia

By

Megan Garlapow, PhD

Modern tools for measuring health-related quality of life may not capture symptoms unique to patients with nontransfusion-dependent thalassemia.

Managing Atrial Fibrillation in Patients With Beta Thalassemia Major

By

Lauren Dembeck, PhD

Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.

Peripheral Blood: An Alternative Source of Stem Cells in Thalassemia

By

Megan Garlapow, PhD

Accessing peripheral blood as a graft source is easier and less invasive than accessing bone marrow.

Serum Ferritin May Unreliably Predict Iron Overload in Patients with Thalassemia Major

By

Sonali Gattani

Iron overload that persists after HSCT can cause long-term organ damage.

Managing Medical Complications of Beta-Thalassemia in Adults: An Experience-Based Perspective

By

Lauren Dembeck, PhD

Mortality in beta-thalassemia has decreased due to medical advances, allowing physicians to observe and manage disease-related complications in adult patients.